Navigation Links
Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
Date:5/27/2008

BURLINGAME, Calif., May 27 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announced today that it has developed its 1000th new rabbit monoclonal antibody. Each antibody has been created, tested and QC'd in house utilizing Epitomics' proprietary rabbit monoclonal antibody technology. "We are very excited to have reached this milestone in a short period of time. This demonstrated the robustness of our technology and development pipeline," said Dr. Guo-Liang Yu, President and CEO of Epitomics Inc. "While thousands of antibodies exist in the market our Rabbit Monoclonal antibody technology has allowed for the development of monoclonal antibodies that were previously only possible to develop as a polyclonal antibody if at all," said Dr. Yu, "many of the targets for which we have developed a Rabbit Monoclonal, no other monoclonal antibody had existed previously."

Epitomics is the exclusive provider of a proprietary method for making monoclonal antibodies from rabbits rather the conventional method of starting with mice. The advantages of Epitomics' rabbit monoclonal antibodies (RabMAbs(TM)) include high specificity and affinity which provide excellent results in a variety of commonly used immunoassays. "Each one of our rabbit monoclonal antibodies undergoes stringent testing in five major immunoassays including Western blotting, Immunohistochemistry, Immunofluorescence, Immunopreciptation and Flow Cytometry, before being released," said Dr. Peter Li, Senior VP of Product Development, "our rabbit monoclonals are among the most extensively characterized antibodies available." The complete list of Rabbit Monoclonals including background information and data for each antibody is available for viewing on Epitomics website.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(TM) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. The Company is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. More information about Epitomics can be found at http://www.epitomics.com


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NicOx Announces Departure of Damian Marron for CEO Position
2. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
3. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
4. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
7. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
8. Amarin Announces Completion of the First Tranche of $60 Million Private Placement
9. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
10. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
11. Biopure Announces 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... YORK , Jan. 17, 2017 ... grow at a CAGR of around 7.5% over ... by 2025. Some of the prominent trends that ... growing incidences of diseases & graft transplant surgeries ... on Material the market is categorized into immunomodulatory ...
(Date:1/17/2017)... Mass. , Jan. 17, 2017   Pulmatrix, ... stage biopharmaceutical company developing innovative inhaled therapies to address ... for treating fungal infections in the lungs of CF ... Disease Product" (QIDP) by the U.S. Food & Drug ... which is designed to speed the development of novel ...
(Date:1/17/2017)... MANHASSET, N.Y. , Jan. 17, 2017 /PRNewswire-USNewswire/ ... to speed the advance of precision cancer research. ... State,s largest health care provider, Northwell ... each year. Indivumed, GmbH is a ... individualize anti-cancer medical therapies. Together they will greatly ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... global provider of learning and performance management systems for high-consequence industries, announced today ... , “In the life sciences industry, organizations must pay much more attention to ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
Breaking Biology News(10 mins):